melanoma

arrow choose one big pick forward many
Biotech

Scancell picks winner from phase 2 cancer vaccine face-off

Scancell linked iSCIB1+ to a 69% response rate in advanced melanoma, leading the biotech to pick the next-generation candidate over its older sibling.
Nick Paul Taylor Jul 22, 2025 9:38am
Image of a neon sign with the word no lit up next to an unlit yes

Replimune's request for melanoma approval rejected by FDA

Jul 22, 2025 8:45am
pendulum silver metallic spheres on coloured background with drop shadow

As investors pivot from cell therapy, Immatics keeps the faith

Jun 6, 2025 3:50am
pile of cash piggy bank money cash dollars bills spend

Pathos AI's $365M series D to fund trial of Novo tumor drug

May 15, 2025 10:20am
An open book with pages turning on a wooden table set

Erasca looks to partner off late-stage melanoma asset

May 13, 2025 10:38am
frog leapfrog jump climb over

Immatics leaps into phase 3 on strength of early-stage PFS data

Oct 10, 2024 8:49am